Medical Oncology Branch and Affiliates
Head, Experimental Therapeutics Section
Senior Investigator

National Cancer Institute
9000 Rockville Pike
Building 10, Room 12C103
Bethesda, MD 20892

Phone: 301-496-2631
Fax: 301-402-1608
fojot@mail.nih.gov

Dr. Fojo was born in Havana, Cuba, moved to the United States with his family in 1960, and became a U.S. citizen in 1970. He received his M.D. and Ph.D. from the University of Miami. He completed 3 years of training in internal medicine at Washington University/Barnes Hospital in St. Louis, and after a year as chief resident came to the NCI as a clinical associate in the Medicine Branch, now the Cancer Therapeutics Branch. After 3 years with Drs. Ira Pastan and Michael Gottesman, he assumed the position of senior investigator in the Cancer Therapeutics Branch.

Dr. Fojo's Clinical Trial(s):

NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with adrenocortical carcinoma, renal cell carcinoma, cervical cancer, and medullary thyroid cancer. Click on the trial(s) below for additional details, including a summary of eligibility criteria, study outline, and information on how to contact the study team directly.

A Targeted Phase I Trial of ZD6474 (Vandetanib; ZACTIMA®) Plus the Proteasome Inhibitor Bortezomib (Velcade®) in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) NCI-09-C-0089

A Phase II Clinical Trial of Ixabepilone (Ixempra, BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer NCI-09-C-0037

First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Etoposide, Doxorubicin, Cisplatin and Mitotane vs. Streptozotocin and Mitotane NCI-08-C-0176

A Phase II Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma NCI-02-C-0130